publication venue for
- Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.. 27. 2021
- Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.. 27. 2020
- Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. 24. 2017
- No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. 23. 2016
- Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar.. 19. 2012
- Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis.. 18. 2011
- Fatigue and quality of life in pediatric multiple sclerosis.. 15. 2009
- Longitudinal correlates of fatigue in multiple sclerosis.. 15. 2009
- Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence.. 14. 2008
- Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.. 13. 2007
- Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group.. 8. 2002
- PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.. 25. 2019
- Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. 24. 2017
- Lessons from precision medicine in rheumatology. 2020